Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Novartis

Novartis to Test Efficacy of Old Malaria Drug Against COVID-19

John Miller  |  April 21, 2020

ZURICH (Reuters)—Swiss drugmaker Novartis AG says it will test the malaria drug hydroxychloroquine (HCQ) in a randomized trial to see if the much talked about medicine is actually effective against COVID-19, the illness caused by the novel coronavirus. The company hopes to have data on its efficacy by June, a lead researcher for the trial…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19Hydroxychloroquine (HCQ)Novartis AG

Novartis, Merck & Allergan Join Those Raising U.S. Drug Prices for 2020

Natasha Yetman  |  January 7, 2020

NEW YORK (Reuters)—Novartis AG, Merck & Co Inc. and Allergan Plc. were among companies that raised U.S. prices on more than 100 prescription medicines on Jan. 4, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. That is above the average…

Filed under:Drug Updates Tagged with:costsdrug costDrugs

FDA Rejects Novartis Bid to Repurpose Inflammation Drug for Heart Attacks

John Miller  |  October 22, 2018

ZURICH (Reuters)—The U.S. Food and Drug Administration (FDA) has rejected Novartis’s bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, according to the Swiss drugmaker. The company received an FDA letter turning down its bid to make canakinumab a targeted therapy for those…

Filed under:Drug Updates Tagged with:canakinumabcardiovascularFamilial Mediterranean feverFDAheartNovartisU.S. Food and Drug Administration (FDA)

Novartis Receives EU Approval for Infliximab Biosimilar Zessly

Reuters Staff  |  May 30, 2018

ZURICH (Reuters)—Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases. Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult and pediatric Crohn’s disease, adult and pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis,…

Filed under:Drug Updates Tagged with:EU approvalinfliximab biosimilarNovartisZessly

Novartis, U.S. Partner Plan Remote Trials to Boost Participation

Reuters Staff  |  March 8, 2018

ZURICH (Reuters)—Novartis plans up to 10 clinical trials over three years using a U.S. partner’s mobile technology to help free patients from burdensome hospital trips as the Swiss drugmaker aims to boost study participation and cut costs. Novartis said on Wednesday it would work with Science 37, a California-based company that provides technology including smart…

Filed under:Uncategorized Tagged with:Novartisremote trialsScience 37video-based telemedicine

Novartis to Shut U.S. Generics Plant, Cut 450 Jobs

Reuters Staff  |  October 19, 2017

ZURICH (Reuters)—Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in Colorado and discontinues some products in the face of intense price pressures. “To remain competitive in the U.S., Novartis will discontinue or divest limited growth products in saturated…

Filed under:Uncategorized Tagged with:job cutsNovartisSandoz divisionU.S. generics plant

Novartis Bid to Sell New Biosimilar Crimped by U.S. Court Battles

John Miller  |  September 1, 2016

ZURICH (Reuters)—Novartis has won U.S. approval for a copy of Amgen’s blockbuster arthritis drug Enbrel, but the Swiss drugmaker’s bid to muscle in on the medicine’s $4.7 billion in annual U.S. revenue remains blocked by court battles. Novartis’s Sandoz unit said on Tuesday the U.S. Food and Drug Administration (FDA) approved Erelzi, its biosimilar copy…

Filed under:Biologics/DMARDsDrug UpdatesProfessional Topics Tagged with:Biologics & BiosimilarsEnbrelNovartis

FDA Panel Supports Novartis Biosimilar of Etanercept

Reuters Staff  |  July 14, 2016

(Reuters)—Novartis AG’s cheaper version of Amgen Inc.’s arthritis drug etanercept (Enbrel) is highly similar in potency and safety to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The panel voted 20–0 that there is no clinically meaningful difference between Novartis’s drug, a biologic made…

Filed under:Biologics/DMARDsDrug Updates Tagged with:AmgenBiosimilarsetanerceptFDAFood and Drug AdministrationNovartis

Roche & Novartis Face Off in Biosimilar Drug Battle

John Miller  |  May 31, 2016

ZURICH (Reuters)—Switzerland’s biggest drugmakers are clashing over cheaper copies of pricey biotech drugs—one reason why Novartis is considering selling its $14 billion stake in cross-town rival Roche. With a copycat of Roche’s blood cancer drug Rituxan (rituximab) pending European approval, Novartis aims to muscle in on a share of sales that last year hit 7…

Filed under:Drug Updates Tagged with:BiosimilarsBusinessgeneric drugsNovartisRemicaderituximabRoche

Novartis Signs $170 Million Immuno-Oncology Pact with Surface

John Miller  |  January 12, 2016

ZURICH (Reuters)—Novartis AG has struck a $170 million alliance with U.S.-based Surface Oncology as it seeks to boost its portfolio of medicines that help the body’s immune system fight cancer. The accord, which it announced on Monday, gives Novartis access to four pre-clinical programs aiming to help prevent tumors from evading the immune system, including…

Filed under:Drug Updates Tagged with:Cancerimmune responseImmune SystemImmuno-OncologyNovartisT cell

  • 1
  • 2
  • 3
  • …
  • 13
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences